Kaplan Fox is Investigating Potential Securities Law Violations Against Iovance Biotherapeutics, Inc. (IOVA)
NEW YORK, NY - May 15, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are an Iovance investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571.
On May 8, 2025, after the markets closed, Iovance announced its first quarter 2025 financial results. The Company revealed that total product revenue for the quarter was $49.3 million, a decline from the prior quarter's reported revenue of $73.7 million. The Company also disclosed that full fiscal year 2025 revenue guidance was being revised to $250 million to $300 million from previous guidance of $450 million to $475 million. Iovance stated that it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was approved by the U.S. Food and Drug Administration in February 2024 and was commercially launched in the first half of 2024.
Following this news, the price of Iovance stock fell $1.42 per share, nearly 45%, to close at $1.75 per share on May 9, 2025.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
[email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
[email protected]
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/iovance-biotherapeutics-inc/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
30 minutes ago
- Business Insider
SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst
TD Cowen analyst Shaul Eyal maintained a Buy rating on SailPoint, Inc. (SAIL – Research Report) today. The company's shares closed today at $22.53. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Eyal is a top 25 analyst with an average return of 26.7% and a 69.56% success rate. Eyal covers the Technology sector, focusing on stocks such as Cloudflare, SailPoint, Inc., and Check Point. In addition to TD Cowen, SailPoint, Inc. also received a Buy from Barclays's Saket Kalia in a report issued on June 3. However, today, Mizuho Securities reiterated a Hold rating on SailPoint, Inc. (NASDAQ: SAIL). SAIL market cap is currently $10.94B and has a P/E ratio of -17.86. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SAIL in relation to earlier this year.
Yahoo
34 minutes ago
- Yahoo
NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion
NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 AI Stocks on Wall Street's Radar. One of the most notable analyst calls on Tuesday, June 10, was for NVIDIA Corporation (NASDAQ:NVDA). Bank of America reiterated the stock as 'Buy,' stating that data center demand trends remain robust for Nvidia. 'Developing AI infrastructure leveraging local datasets and workforces is a rapidly growing global phenomenon and we expect it to contribute $50bn+ annually or 10%+ of long-term AI addressable market.' A powerful aerial view of the company's data center, exemplifying the digital services and informatics being offered. In other latest news, Nvidia Corporation and Hewlett-Packard Enterprise said on Tuesday that they are partnering with the Leibniz Supercomputing Centre to build a new supercomputer using Nvidia's next-generation chips. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
